Use of a molecular bacterial load assay to distinguish between active TB and post-TB lung disease
Citation
Mbelele , P M , Sabiiti , W , Heysell , S K , Sauli , E , Mpolya , E A , Mfinanga , S , Gillespie , S H , Addo , K K , Kibiki , G , Sloan , D J & Mpagama , S G 2022 , ' Use of a molecular bacterial load assay to distinguish between active TB and post-TB lung disease ' , International Journal of Tuberculosis and Lung Disease , vol. 26 , no. 3 , pp. 276-278 . https://doi.org/10.5588/ijtld.21.0459
Publication
International Journal of Tuberculosis and Lung Disease
Status
Peer reviewed
ISSN
1027-3719Type
Journal item
Rights
Copyright © 2022 The Author(s). Original content from this work may be used under the terms of the Creative Commons Attribution International 4.0 licence. Any further distribution of this work must maintain attribution to the author(s) and the title of the work, journal citation and DOI.
Description
Authors acknowledge financial support from the EDCTP2 programme supported by the European Union project (grant #: TMA2016SF-1463-REMODELTZ) and DELTAS Africa Initiative (Afrique One-ASPIRE /DEL-15-008). The Afrique One-ASPIRE is funded by a consortium of donors including the African Academy of Sciences, Alliance for Accelerating Excellence in Science in Africa, the New Partnership for Africa's Development Planning and Coordinating Agency, the Wellcome Trust (107753/A/15/Z), and the UK Government. PMM, SKH and SGM were also supported by NIH U01AI115594.Collections
Items in the St Andrews Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Related items
Showing items related by title, author, creator and subject.
-
A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer’s disease and Parkinson’s disease
McGhee, David J. M.; Ritchie, Craig W.; Zajicek, John Peter; Counsell, Carl E. (2016-06-16) - Journal articleBackground. Disease-modification clinical trials in neurodegenerative disorders have struggled to separate symptomatic effects of putative agents from disease-modification. In response, a variety of clinical trial designs ... -
A systematic review of biomarkers for disease progression in Parkinson's disease
McGhee, David J. M.; Royle, Pamela L.; Thompson, Paul A.; Wright, David E.; Zajicek, John P.; Counsell, Carl E. (2013-04-12) - Journal articleBACKGROUND: Using surrogate biomarkers for disease progression as endpoints in neuroprotective clinical trials may help differentiate symptomatic effects of potential neuroprotective agents from true disease-modifying ... -
A systematic review of biomarkers for disease progression in Alzheimer's disease
McGhee, David J. M.; Ritchie, Craig W.; Thompson, Paul A.; Wright, David E.; Zajicek, John P.; Counsell, Carl E. (2014-02-18) - Journal articleBACKGROUND: Using surrogate biomarkers for disease progression as endpoints in neuroprotective clinical trials may help differentiate symptomatic effects of potential neuroprotective agents from true slowing of the ...